Unique ID issued by UMIN | UMIN000013539 |
---|---|
Receipt number | R000015819 |
Scientific Title | Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients |
Date of disclosure of the study information | 2014/03/31 |
Last modified on | 2016/03/24 14:58:16 |
Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients
Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients
Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients
Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients
Japan |
Type 2 diabetes mellitus
Endocrinology and Metabolism |
Others
NO
Possibility to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients combined with metformin , GLP-1 receptor agonist, and SGLT-2 inhibitor
Safety,Efficacy
Exploratory
Explanatory
Not applicable
Duration of insulin usage, Rate of insulin withdrawal, Change rate of body weight, Incidence rate of hypoglycemia
Diabetic duration, Body weight, HOMA-B,HOMA-R, delta C-peptide, Blood pressure, LDL-C, HDL-C, TG, UA, Ketone bodies in blood, FFA, Renin activity, Aldosterone, Glucose concentration in urine, Microalbumin in urine, Protein in urine, NAG in urine, Beta-2 microglobulin in urine, Ca excretion in urine, C-peptide in urine, Amino acids in urine
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is not considered as adjustment factor.
NO
Pseudo-randomization
2
Treatment
Medicine |
SGLT-2 inhibitor(-)
SGLT-2 inhibitor(+)
20 | years-old | <= |
75 | years-old | > |
Male and Female
1.HbA1c >=8.0 inadequately controlled type 2 diabetic patients
2. age >=20, <75
3.BMI >=22 kg/m2, and eGFR >=45 ml/min/1.73m2
4. patients who can get written consent
1.age <20, >=75
2.BMI <22 kg/m2
3.eGFR <45 ml/min/1.73m2
4. anti-GAD antibody titer >=10 or insulin-dependent
5. patients who have anemia (Hb male <12 g/dl, female <11 g/dl)
6. patients who have cancer, or infection
7. patients judged to be disqualified to this research by physicians
20
1st name | |
Middle name | |
Last name | Hiroshi Maegawa |
Shiga University of Medical Science, Department of Internal Medicine
Devision of Endocrinology and Metabolism
Seta Tsukinowa-cho, Otsu, Shiga
+81-77-548-2222
maegawa@belle.shiga-med.ac.jp
1st name | |
Middle name | |
Last name | Ken-ichi Nemoto |
Shiga University of Medical Science, Department of Internal Medicine
Devision of Endocrinology and Metabolism
Seta Tsukinowa-cho, Otsu, Shiga
+81-77-548-2223
knemoto@belle.shiga-med.ac.jp
Shiga University of Medical Science
Department of Internal Medicine
Division of Diabetology, Nephrology, Neurology
Shiga University of Medical Science
Department of Internal Medicine
Division of Diabetology, Nephrology, Neurology
Self funding
NO
滋賀医科大学附属病院
2014 | Year | 03 | Month | 31 | Day |
Published
Completed
2014 | Year | 03 | Month | 27 | Day |
2014 | Year | 03 | Month | 31 | Day |
2015 | Year | 03 | Month | 31 | Day |
2015 | Year | 03 | Month | 31 | Day |
2015 | Year | 04 | Month | 10 | Day |
2015 | Year | 09 | Month | 30 | Day |
2014 | Year | 03 | Month | 27 | Day |
2016 | Year | 03 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015819
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |